<img class="lazy" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://cdn.cancerletter.com/media/2021/03/17053004/TCL-logo-horizontal-white.png" alt="" >

Monica Bertagnolli’s NIH confirmation hearing scheduled

October 13, 2023

DOWNLOAD PDF TABLE OF CONTENTS

The Senate confirmation hearing for NCI Director Monica Bertagnolli, who has been nominated for the job of NIH director, has been scheduled for Oct. 18.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

DOWNLOAD THE PDF

Table of Contents

YOU MAY BE INTERESTED IN

Clinical Trials & Tribulations

Single-cell based precision oncology: First steps in addressing and overcoming tumor heterogeneity

Tumor heterogeneity is a well-recognized hurdle to successful cancer therapy, often leading to resistance and treatment failure.

By Sanju Sinha and Eytan Ruppin

NCI renews MUSC Hollings support grant with “outstanding” rating

NCI has renewed MUSC Hollings Cancer Center’s five-year Cancer Center Support Grant, with an overall rating of “outstanding.”

Pooled analysis questions reliability of an endpoint used in multi-cancer detection trials

An analysis by researchers from the International Agency for Research on Cancer casts doubt on validity of an endpoint used in key studies of multi-cancer detection tests.

By Jacquelyn Cobb

NCI Director's Report

Rathmell: To improve funding outlook, we must reverse distrust in science

With NCI funding expected to remain flat through fiscal year 2025, health professionals and leaders in oncology should use this time to amp up institutional efforts to collaborate and rebuild trust in science, NCI Director Kimryn Rathmell said.

By Matthew Bin Han Ong

NCI creates Cancer Equity Leaders group to improve cancer health equity

To address inequities in cancer health, NCI is collaborating with a diverse team of experts and cancer center directors—named the Cancer Equity Leaders (CEL)—to learn from communities and inform workforce development as well as outreach initiatives.

By Matthew Bin Han Ong

NCI maintains paylines for early-stage investigators, cuts funding for other R01s and noncompeting grants in FY24

NCI is lowering paylines for R01 grants for established and new investigators to the 10th percentile, down from the 12th percentile in FY23.

By Matthew Bin Han Ong